Literature DB >> 26437080

Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status.

Samantha Kendrick1, Katalin Tus1, George Wright2, Elaine S Jaffe3, Andreas Rosenwald4, Elías Campo5, Wing Chung Chan6, Joseph M Connors7, Rita M Braziel8, German Ott9, Jan Delabie10, James R Cook11, Dennis D Weisenburger6, Timothy C Greiner12, Kai Fu12, Louis M Staudt13, Randy D Gascoyne7,14, David W Scott7, Lisa M Rimsza1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26437080      PMCID: PMC5937932          DOI: 10.3109/10428194.2015.1072767

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  13 in total

1.  Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Tina Marie Green; Ken H Young; Carlo Visco; Zijun Y Xu-Monette; Attilio Orazi; Ronald S Go; Ole Nielsen; Ole V Gadeberg; Torben Mourits-Andersen; Mikael Frederiksen; Lars Møller Pedersen; Michael Boe Møller
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.

Authors:  David W Scott; George W Wright; P Mickey Williams; Chih-Jian Lih; William Walsh; Elaine S Jaffe; Andreas Rosenwald; Elias Campo; Wing C Chan; Joseph M Connors; Erlend B Smeland; Anja Mottok; Rita M Braziel; German Ott; Jan Delabie; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Timothy C Greiner; Betty J Glinsmann-Gibson; Kai Fu; Louis M Staudt; Randy D Gascoyne; Lisa M Rimsza
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

3.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

4.  MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.

Authors:  Anamarija M Perry; Yuridia Alvarado-Bernal; Javier A Laurini; Lynette M Smith; Graham W Slack; King L Tan; Laurie H Sehn; Kai Fu; Patricia Aoun; Timothy C Greiner; Wing C Chan; Philip J Bierman; Robert G Bociek; James O Armitage; Julie M Vose; Randy D Gascoyne; Dennis D Weisenburger
Journal:  Br J Haematol       Date:  2014-02-08       Impact factor: 6.998

5.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

6.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.

Authors:  A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

7.  BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma.

Authors:  Samantha L Kendrick; Lucas Redd; Andrea Muranyi; Leigh A Henricksen; Stacey Stanislaw; Lynette M Smith; Anamarija M Perry; Kai Fu; Dennis D Weisenburger; Andreas Rosenwald; German Ott; Randy D Gascoyne; Elaine S Jaffe; Elías Campo; Jan Delabie; Rita M Braziel; James R Cook; Raymond R Tubbs; Louis M Staudt; Wing Chung Chan; Christian Steidl; Thomas M Grogan; Lisa M Rimsza
Journal:  Hum Pathol       Date:  2014-06-26       Impact factor: 3.466

8.  MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.

Authors:  Heike Horn; Marita Ziepert; Claudia Becher; Thomas F E Barth; Heinz-Wolfram Bernd; Alfred C Feller; Wolfram Klapper; Michael Hummel; Harald Stein; Martin-Leo Hansmann; Christopher Schmelter; Peter Möller; Sergio Cogliatti; Michael Pfreundschuh; Norbert Schmitz; Lorenz Trümper; Reiner Siebert; Markus Loeffler; Andreas Rosenwald; German Ott
Journal:  Blood       Date:  2013-01-18       Impact factor: 22.113

9.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

10.  Stromal gene signatures in large-B-cell lymphomas.

Authors:  G Lenz; G Wright; S S Dave; W Xiao; J Powell; H Zhao; W Xu; B Tan; N Goldschmidt; J Iqbal; J Vose; M Bast; K Fu; D D Weisenburger; T C Greiner; J O Armitage; A Kyle; L May; R D Gascoyne; J M Connors; G Troen; H Holte; S Kvaloy; D Dierickx; G Verhoef; J Delabie; E B Smeland; P Jares; A Martinez; A Lopez-Guillermo; E Montserrat; E Campo; R M Braziel; T P Miller; L M Rimsza; J R Cook; B Pohlman; J Sweetenham; R R Tubbs; R I Fisher; E Hartmann; A Rosenwald; G Ott; H-K Muller-Hermelink; D Wrench; T A Lister; E S Jaffe; W H Wilson; W C Chan; L M Staudt
Journal:  N Engl J Med       Date:  2008-11-27       Impact factor: 91.245

View more
  6 in total

1.  A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL.

Authors:  Zijun Y Xu-Monette; Hongwei Zhang; Feng Zhu; Alexandar Tzankov; Govind Bhagat; Carlo Visco; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Eric D Hsi; Hua You; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Benjamin M Parsons; J Han van Krieken; Miguel A Piris; Jane N Winter; Fredrick B Hagemeister; Babak Shahbaba; Ivan De Dios; Hong Zhang; Yong Li; Bing Xu; Maher Albitar; Ken H Young
Journal:  Blood Adv       Date:  2020-07-28

2.  Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities.

Authors:  Elizabeth A Morgan; M Patrick Sweeney; Tamiwe Tomoka; Nadja Kopp; Daniel Gusenleitner; Robert A Redd; Christopher D Carey; Leo Masamba; Steve Kamiza; Geraldine S Pinkus; Donna S Neuberg; Scott J Rodig; Danny A Milner; David M Weinstock
Journal:  Blood Adv       Date:  2016-11-22

Review 3.  Clinical applications of genome studies.

Authors:  Anas Younes
Journal:  Hematol Oncol       Date:  2017-06       Impact factor: 5.271

Review 4.  Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma.

Authors:  Grzegorz S Nowakowski; Tatyana Feldman; Lisa M Rimsza; Jason R Westin; Thomas E Witzig; Pier Luigi Zinzani
Journal:  Blood Cancer J       Date:  2019-05-16       Impact factor: 11.037

5.  A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform.

Authors:  Wei Zhang; Qilin Ao; Yuqi Guan; Zhoujie Zhu; Dong Kuang; Monica M Q Li; Kefeng Shen; Meilan Zhang; Jiachen Wang; Li Yang; Haodong Cai; Ying Wang; Ken H Young; Jianfeng Zhou; Min Xiao
Journal:  Mod Pathol       Date:  2021-11-20       Impact factor: 8.209

6.  Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma.

Authors:  Maysaa Abdulla; Peter Hollander; Tatjana Pandzic; Larry Mansouri; Susanne Bram Ednersson; Per-Ola Andersson; Magnus Hultdin; Maja Fors; Martin Erlanson; Sofie Degerman; Helga Munch Petersen; Fazila Asmar; Kirsten Grønbaek; Gunilla Enblad; Lucia Cavelier; Richard Rosenquist; Rose-Marie Amini
Journal:  Am J Hematol       Date:  2019-11-07       Impact factor: 10.047

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.